Revvity, Inc.
NYSE:RVTYMedical - Diagnostics & Research
-$3.40 today
- Market cap
- $17.02B
- Beta
- 1.11
- P/E (TTM)
- 45.4
- EPS (TTM)
- $2.15
- Dividend yield
- 0.29%
Volume 1.09M
Average 1.27M
RVTY Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Revvity, Inc.NYSE: RVTY
Accounts Receivables · Q2 FY2026 · quarter ended Jul 2026
Accounts receivables declines year over year
Q2 FY2026 accounts receivables of $17.63M (cash outflow) fell 56.0% year over year, behind the -46.7% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 3.5% of revenue in FY2025, up 3.0 pp from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -56.0% toward the trailing-twelve-month pace of -46.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (101.02M) USD
- Year-over-year change
- -532.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | (101.02M) | -532.6% |
| FY2024 | 2024-12-29 | (15.97M) | -77.5% |
| FY2023 | 2023-12-31 | (9M) | -113.6% |
| FY2022 | 2022-12-31 | 66.09M | -60.1% |
| FY2021 | 2021-12-31 | 165.59M | — |
Accounts Receivables vs competitors
How RVTY compares with its peers on the latest reported figures
- RVTY's LTM Jul 2026 accounts receivables of $35.21M is the 6th largest of the 11 companies compared; the peer median is $39.17M.
- Its year-over-year change of -46.7% is the 8th highest of 11, against a peer median of -2.4%.
- Accounts receivables amounts to 1.2% of revenue for RVTY, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $880.37M | +846.5% | -26.2% | 19.0% | |
| LTM Sep 2026 | $174M | -19.4% | -23.2% | 0.7% | |
| LTM Jul 2026 | $89M | -14.4% | -22.6% | 1.2% | |
| LTM Jun 2026 | $45.54M | +114.9% | -17.8% | 1.1% | |
| LTM Sep 2026 | $45.43M | -188.5% | -22.7% | 3.7% | |
| LTM Jul 2026 | $35.21M | -46.7% | — | 1.2% | |
| LTM Jun 2026 | $32.91M | -1705.3% | — | 0.8% | |
| LTM Jun 2026 | $8.1M | +148.2% | — | 0.3% | |
| LTM Jun 2026 | $7.31M | -67.7% | — | 0.3% | |
| LTM Mar 2026 | $3.21M | +9.6% | +14.8% | 1.3% | |
| LTM Sep 2026 | $0 | +100.0% | -0.3% | 0.0% | |
| Peer median (excluding RVTY) | $39.17M | -2.4% | -22.6% | 1.0% | |
Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 889.44M | 512.68M | 179.5M | 283.07M | 241.2M |
| Depreciation & Amortization | 311.44M | 427M | 431.77M | 427.85M | 405.34M |
| Deferred Income Tax | (53.4M) | (107.41M) | (97.48M) | (110.31M) | (61.48M) |
| Stock-Based Compensation | 29.68M | 51.52M | 41.41M | 37.81M | 22.85M |
| Change in Working Capital | 132.99M | (262.97M) | (391.35M) | (18.31M) | (96.78M) |
| Accounts Receivables | 165.59M | 66.09M | (9M) | (15.97M) | (101.02M) |
| Inventory | 32.28M | (48.63M) | (14.11M) | 45.09M | 14.78M |
| Accounts Payables | (7.58M) | (43.8M) | (76.43M) | (26.03M) | 7.35M |
| Other Working Capital | (57.3M) | (236.62M) | (291.81M) | (21.4M) | (17.89M) |
| Other Non-Cash Items | 100.61M | 59M | (72.58M) | 8.18M | 70.65M |
| Operating Cash Flow | 1.41B | 679.81M | 91.27M | 628.3M | 581.78M |
| Capital Expenditures | (86.02M) | (85.63M) | (81.37M) | (86.65M) | (73.52M) |
| Acquisitions (Net) | (3.98B) | 6.99M | (1.93M) | 0 | 0 |
| Purchases of Investments | (23.13M) | (47.18M) | (1.23B) | (6.59M) | (385K) |
| Sales of Investments | 0 | 8.89M | 550M | 712.5M | 0 |
| Other Investing Activities | (22.96M) | (15.92M) | 2.07B | 156.9M | 56.55M |
| Investing Cash Flow | (4.11B) | (132.85M) | 1.31B | 776.16M | (17.35M) |
| Debt Repayment | 3.04B | (559.17M) | (517.49M) | (723.07M) | (521K) |
| Common Stock Issued | 25.12M | 14.11M | 0 | 0 | 2.93M |
| Common Stock Repurchased | (73.07M) | (80.64M) | (388.88M) | (369.58M) | (820.82M) |
| Dividends Paid | (32.37M) | (35.34M) | (34.97M) | (34.45M) | (32.8M) |
| Other Financing Activities | (21M) | (767K) | (5.79M) | (1.13M) | (3.84M) |
| Financing Cash Flow | 2.94B | (661.8M) | (947.12M) | (1.13B) | (855.05M) |
| Effect of Forex Changes | (22.93M) | (33.75M) | (14.05M) | (26.15M) | 46.04M |
| Net Change in Cash | 216.72M | (148.59M) | 443.63M | 250.08M | (244.59M) |
| Free Cash Flow | 1.32B | 594.18M | 9.9M | 541.65M | 508.26M |
Revvity, Inc.
NYSE:RVTY
Intrinsic Alpha fair value
Locked
Current Price
$152.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.